The CoreX™ Platform
Antibody-Dependent Cellular Cytotoxicity (ADCC) plays a pivotal role in cancer treatment. It is a crucial immune effector function that serves as a key mechanism of action of therapeutic monoclonal antibodies (mAb) in eliminating various cancer cell types(1,2,3). When a therapeutic mAb targets cancer cells, it triggers an immune response. This response involves natural killer (NK) cells, which locate the mAb-cancer cell complex, bind to the complex, and release cytotoxic factors to destroy the cancer cell. The efficacy of this process is highly dependent on the binding of the NK cell to the mAb-cancer cell complex(4). The stronger the binding interaction, the more efficiently the cancer cells are destroyed(5).
Core fucosylation reduces ADCC efficacy. The binding of the NK cells to the mAb-cancer cell complex is significantly influenced by a fucose molecule attached to the conserved N-glycosylation site ASN297, known as core fucosylation(2). Research has shown that reducing core fucose increases the strength of the binding interaction, and it is widely accepted that removing core fucose is the best approach to improving ADCC activity(2).
The CoreX™ Platform leverages the ability to use existing antibody therapeutic drugs to produce therapeutically superior, best-in-class, biobetter antibody therapeutics. Score Pharma has developed a cell culture additive approach that affects the cellular process of core fucosylation. Using Score Pharma’s additives during antibody production results in an afucosylated biobetter antibody therapeutic without developing new methods.
